Lucid Diagnostics Inc. (LUCD): Multiplikator Forward P/S
Slow adoption rates for EsoGuard insurance and marketing expenses are weighing on Lucid Diagnostics Inc. (LUCD) capital. However, the optimization of distribution centers is improving profitability, and the P/S expectations for the company provided by the GURU.Markets system confirm this trend, where 14.60 expresses the latest metric level. Efficient express delivery of biomaterials to laboratories accelerates oncology diagnoses, ensuring the accuracy of results.
Rincian metrik komprehensif lan analitis Lucid Diagnostics, Inc (LUCD)
- rega saham lan target rega konsensus:
- data kapitalisasi bursa:
- statistik nilai buku emiten:
- data tingkat utang lan likuiditas finansial:
Rasio Total Utang marang Ekuitas Lucid Diagnostics Inc.|LUCD - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal Lucid Diagnostics Inc.|LUCD - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku Lucid Diagnostics, Inc|LUCD - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Lucid Diagnostics|Rasio cepet luciddx.com
- rincian asil keuangan lan kelipatan valuasi:
LUCD - Bathi resik taunan|Bathi sing dikarepake Lucid Diagnostics Inc.|LUCD - Pangali rega marang bathi|Rega marang bathi mangsa ngarep Lucid Diagnostics Inc|LUCD - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Lucid Diagnostics, Inc|LUCD - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Lucid Diagnostics|LUCD - Bathi saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan luciddx.com|LUCD - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Lucid Diagnostics Inc.
- indikator volume dodolan lan pendapatan:
Pambiji fundamental perusahaan:Lucid Diagnostics LUCD
This ratio determines the market value of a business relative to expected future sales, allowing an investor to assess the premium paid per unit of future revenue. By analyzing the forward P/S multiple on the GURU.Markets platform, one can confirm the resilience of Lucid Diagnostics Inc. (LUCD), as the defensive nature of esophageal cancer diagnostics minimizes valuation volatility risks during economic downturns.
Analisis perusahaan pesaing
Agilent - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Quest Diagnostics Inc. DGX|Illumina Corp - Multiplikator Forward P/S|Exact Sciences Inc. (EXAS) - Multiplikator forward rega marang pendapatan|RVTY: Multiplikator Forward P/S|BIO - Rasio kapitalisasi marang dodolan sing dikarepake|NNNN (Anbio) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan SHC (Sotera Health Corp)|Multiplikator forward rega marang pendapatan QDEL (QuidelOrtho Corp)|OPK (OPKO Health Corp.) - Rega forward marang dodolan|Multiplikator Forward P/S CDNA (CareDx, Inc)|MRVI: Kapitalisasi marang prakiraan pendapatan|Fulgent Genetics - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Standard BioTools Inc LAB|CTKB: Multiplikator Forward P/S|OraSure Corp (OSUR) - Multiplikator Forward P/S|XGN (Exagen Inc) - Multiplikator Forward P/S|MDXH - Prakiraan rega marang pendapatan|Rasio rega marang prakiraan pendapatan Prenetics Global (PRE)|imdxinc.com - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Trinity Biotech TRIB|ProPhase Labs Corp (PRPH) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|AIMD - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake codiagnostics.com CODX|HSCS (HeartSciences) - Multiplikator forward rega marang pendapatan|BMRA: Rasio rega marang pendapatan sing dikarepake|CDIO (Cardio Diagnostics Holdings Inc.) - Multiplikator Forward P/S|Onconetix Corporation (ONCO) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S VRAX|Multiplikator forward rega marang pendapatan bluejaydx.com BJDX|Rasio rega marang prakiraan pendapatan Aspira Women's Health Inc. AWH|Rasio kapitalisasi marang dodolan sing dikarepake Accelerate Diagnostics Inc. (AXDX)|CNTG: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ENZ (Enzo Biochem, Inc.)|FRES: Multiplikator Forward P/S|GENE - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan 23andMe|Kapitalisasi marang prakiraan pendapatan PMD (Psychemedics Corp.)
